Home > Insider Trading > Filing (0001209191-20-036385)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1346830	Cara Therapeutics Inc.	CARA	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1756991	Joana Goncalves	C/O Cara Therapeutics, Inc. 4 Stamford Plaza, 107 Elm Street, 9Th Fl Stamford CT 06902	Chief Medical Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2020-06-10	30,000	$0.00	46,000	No	4	A	Direct
Common Stock	Disposition	2020-06-12	10,627	$15.20	35,373	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	A	Direct
No	4	S	Direct

Footnotes

Represents the number of shares that vested under a performance-based restricted stock unit award (the "RSU") based on the Issuer's satisfaction of certain performance criteria of the award. In light of the performance-based vesting conditions of the award, such shares were not reportable under Section 16 until vesting was determined, which occurred on June 10, 2020. Each RSU represents the contingent right to receive one share of common stock of the Issuer.
This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on March 12, 2020 to satisfy the tax withholding obligations triggered by the vesting and of the RSUs reported herein as described in greater detail in footnote (1), and does not represent a discretionary trade by the Reporting Person.
Represents the number of shares required to be sold by the Reporting Person to cover tax withholding as described in footnote (2).
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.09 to $15.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4.